Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer.

Cancers (Basel) · 2024 · PMC10813385 · PMID 38254748

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

not quite statistically significantp = 0.06so close (0.05 < p ≤ 0.1)

There was evidence that survival was also better for ping-pong dose modulation compared to no treatment, but it was not quite statistically significant (Cox proportional HR = 0.2, 95% CI = 0.038–1.09, p = 0.06).

also in 55 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.